Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Histone deacetylase (HDAC) inhibitors represent a novel class of anticancer agents with significant therapeutic potential.
• Accurate pharmacodynamic (PD) assessment is crucial for optimizing HDAC inhibitor efficacy in clinical trials.
• Existing methods may lack the sensitivity or versatility required for comprehensive PD evaluation.

Purpose of the Study:

• To develop a sensitive and versatile flow cytometry-based assay for the pharmacodynamic assessment of histone deacetylase (HDAC) inhibitor activity.
• To enable the evaluation of HDAC inhibitors as both monotherapy and in combination regimens.
• To establish a method applicable to various clinical samples, including peripheral blood and bone marrow aspirates.

Main Methods:

• Development of a multiparameter flow cytometric assay using lymphocytes and leukemia cell lines.
• Validation of the assay in peripheral blood from solid tumor patients and bone marrow aspirates from leukemia patients undergoing HDAC inhibitor therapy (MS-275).
• Quantification of protein acetylation levels and correlation with cell lineage antigens, apoptosis markers, and other drug PD markers.

Main Results:

• A highly sensitive single-parameter assay was established, requiring only 50 microliters of whole blood.
• Multiparameter analysis allowed for single-cell correlation of protein acetylation with key biological markers.
• The technique demonstrated robust detection and quantification of protein acetylation in clinical samples.

Conclusions:

• The developed flow cytometry assay provides a sensitive and versatile tool for the pharmacodynamic assessment of HDAC inhibitors.
• This method is suitable for evaluating HDAC inhibitors in both monotherapy and combination therapy settings.
• The technique offers significant advantages for clinical trials investigating HDAC inhibitors in cancer treatment.